Summary
meta-iodobenzylguanidine (MIBG) radiolabelled with iodine-131 is used for diagnosis and treatment of neuroadrenergic neoplasms such as phaeochromocytoma and neuroblastoma. In addition, non-radiolabelled MIBG, administered i.v., is used in several clinical studies. These include palliation of the carcinoid syndrome, in which MIBG proved to be effective in 60% of the patients. Oral MIBG administration might be convenient to maintain palliation and possibly improve the percentage of responders. We have, therefore, investigated the feasibility of oral administration of MIBG in an animal model. Orally administered MIBG demonstrated a bioavailability of 59%, with a maximal tolerated dose of 60 mg kg–1. The first and only toxicity encountered was a decrease in renal function, measured by a reduced clearance of [51Cr]EDTA and accompanied by histological tubular damage. Repeated MIBG administration of 40 mg kg–1for 5 sequential days or of 20 mg kg–1for two courses of 5 sequential days with a 2-day interval did not affect renal clearance and was not accompanied by histological abnormalities in kidney, stomach, intestines, liver, heart, lungs, thymus, salivary glands and testes. Because of a sufficient bioavailability in absence of gastrointestinal toxicity, MIBG is considered suitable for further clinical investigation of repeated oral administration in patients.
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Hoefnagel, C. A., Voûte, P. A., de Kraker, J. & Marcuse, H. R. (1987a). Radionuclide diagnosis and therapy of neural crest tumors using iodine-131 metaiodobenzylguanidine. J Nucl Med 28: 308–314.
Hoefnagel, C. A., den Hartog Jager, F. C. A., Taal, B. G., Abeling, NGGM & Engelsman, E. E. (1987b). The role of I-131-MIBG in the diagnosis and therapy of carcinoids. Eur J Nucl Med 13: 187–191.
Hoefnagel, C. A., Taal, B. G., Sivro, F., Boot, H. & Valdés Olmos, R. A. (1998). Enhancement of I-131 MIBG uptake in carcinoid tumors by administration of unlabelled MIBG. Hybridoma, (in press)
Jaques, S., Tobes, M. C. & Sisson, J. C. (1987). Sodium dependency of uptake of norepinephrine and m-iodobenzylguanidine into cultured human pheochromocytoma cells: evidence for uptake-one. Cancer Res 47: 3920–3928.
Kuin, A., Smets, L. A., Volk, T., Paans, A., Adams, G., Atema, A., Jähde, E., Maas, A., Rajewsky, M. F., Visser, G. & Wood, P. (1994). Reduction of intratumoral pH by the mitochondrial inhibitor m-iodobenzylguanidine and moderate hyperglycemia. Cancer Res 54: 3785–3792.
Kuin, A., Aalders, M., van der Valk, M. A., Frey, A., Schmidt, HHHW & Smets, L. A. (1998). Renal toxicity of the neuron-blocking and mitochondriotropic agent m-iodobenzylguanidine (MIBG). Cancer Chemother Pharmacol 42: 37–45.
Loesberg, C., van Rooij, H., Nooijen, W. J., Meijer, A. J. & Smets, L. A. (1990a). Impaired mitochondrial respiration and stimulated glycolysis by m-iodobenzylguanidine (MIBG). Int J Cancer 46: 276–281.
Loesberg, C., van Rooij, H. & Smets, L. A. (1990b). Meta-iodobenzylguanidine (MIBG), a novel high-affinity substrate for cholera toxin that interferes with cellular mono(ADP-ribosylation). Biochem Biophys Acta 1037: 92–99.
Rutgers, M., Tytgat, G. A. M., Verwijs-Janssen, M., Buitenhuis, C., Voûte, P. A. & Smets, L. A. (1993). Uptake of the neuron-blocking agent meta-iodobenzylguanidine and serotonin by human platelets and neuro-adrenergic tumour cells. Int J Cancer 54: 290–295.
Sisson, J. C. & Wieland, D. M. (1986). Radiolabeled meta-iodobenzylguanidine: pharmacology and clinical studies. Am J Physiol Imaging 1: 96–103.
Smets, L. A., Bout, B. & Wisse, J. (1988). Cytotoxic and antitumor effects of the norepinephrine analogue meta-iodo-benzylguanidine (MIBG). Cancer Chemother Pharmacol 21: 9–13.
Smets, L. A., Janssen, M., Rutgers, M., Ritzen, K. & Buitenhuis, C. (1991). Pharmacokinetics and intracellular distribution of the tumor-targeted radiopharmaceutical m-iodo-benzylguanidine in SK-N-SH neuroblastoma and PC-12 pheochromocytoma cells. Int J Cancer 48: 609–615.
Sparreboom, A., van Asperen, J., Mayer, U., Schinkel, A. H., Smit, J. W., Meijer, D. K. F., Borst, P., Nooijen, W. J., Beijnen, J. H. & van Tellingen, O. (1997). Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine. Proc Natl Acad Sci USA 94: 2031–2035.
Taal, B. G., Hoefnagel, C. A., Valdes Olmos, R. A., Boot, H. & Beijnen, J. H. (1996a). Palliative effect of metaiodobenzylguanidine in metastatic carcinoid tumors. J Clin Oncol 14: 1829–1838.
Taal, B. G., Hoefnagel, C. A., Valdes Olmos, R. A. & Boot, J. H. (1996b). The effect of unlabelled MIBG prior to 131I-MIBG scanning and its potential benefit in the treatment of metastatic carcinoid. Eur J Gastroent Hep 8: A36(abstract)
Wafelman, A. R., Hoefnagel, C. A., Maes, R. A. A. & Beijnen, J. H. (1994). Radioiodinated meta-iodobenzylguanidine: a review of its biodistribution and pharmacokinetics, drug interactions, cytotoxicity and dosimetry. Eur J Nucl Med 21: 545–559.
Wieland, D. M., Wu, J. I., Brown, L. E., Mangner, T. J., Swanson, D. P. & Beierwaltes, W. H. (1980). Radiolabeled adrenergic neuron-blocking agents: adrenomedullary imaging with [131I]iodobenzylguanidine. J Nucl Med 21: 349–353.
Author information
Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Kuin, A., Rutgers, M., Valk, M. et al. Bioavailability and toxicity after oral administration of m-iodobenzylguanidine (MIBG). Br J Cancer 79, 802–806 (1999). https://doi.org/10.1038/sj.bjc.6690128
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bjc.6690128
Keywords
- MIBG
- oral administration
- bioavailability
- toxicity
- carcinoid syndrome
